Fang, Jiali and Genco, Matthew and Caskey, Rachel N (2020) COVID-19 Precipitating Euglycaemic Diabetic Ketoacidosis with SGLT2 Inhibitor Use. European Journal of Case Reports in Internal Medicine, 7 (11). pp. 1-3. ISSN ISSN: 2284-2594
|
Text
1943-Article Text-18033-1-10-20201022.pdf - Published Version Download (202kB) | Preview |
Abstract
Objective: To describe a patient who developed euglycaemic diabetic ketoacidosis (DKA) in the setting of SGLT2 inhibitor use precipitated by COVID-19.Patient and methods: A 52-year-old male with type II diabetes on empagliflozin and no history of DKA presented with symptoms of COVID-19 as well as laboratory findings consistent with euglycaemic DKA. His hospital course was complicated by recurrent episodes of euglycaemic DKA as well as hyperglycaemic DKA. Conclusion: SGLT2 inhibitors should be held as early as possible in COVID-19 cases due to the risk of euglycaemic DKA. These patients should also have more intense glucose monitoring.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Diabetic ketoacidosis, sodium-glucose cotransporter 2 inhibitors, COVID-19, diabetes, empagliflozin |
| Subjects: | 600 Tecnologia - Scienze applicate 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) |
| Depositing User: | Marina Spanti |
| Date Deposited: | 15 Dec 2021 14:00 |
| Last Modified: | 15 Dec 2021 14:00 |
| URI: | http://eprints.bice.rm.cnr.it/id/eprint/21031 |
Actions (login required)
 |
View Item |
